# The neuroimmune microenvironment of peripheral nerve injury: mechanisms, pathophysiology, and therapeutic implications

**Authors:** Wesley S. Warner, Madeline Rose, Stewart Yeoh, Whitney E. Muhlestein, Sama Noroozi Gilandehi, Mark A. Mahan

PMC · DOI: 10.3389/fsurg.2026.1745990 · Frontiers in Surgery · 2026-02-16

## TL;DR

This review explores how immune responses influence nerve regeneration after injury and how these interactions can lead to poor recovery outcomes.

## Contribution

The paper provides a comprehensive synthesis of neuroimmune interactions in peripheral nerve injury and their implications for therapeutic strategies.

## Key findings

- Resident, innate, and adaptive immune responses dynamically shape nerve regeneration and pathophysiology.
- Failed inflammatory resolution and maladaptive neuroimmune interactions may drive poor recovery outcomes.
- Therapeutic approaches like pharmacology, cellular therapies, and hydrogels can modulate the immune microenvironment to improve regeneration.

## Abstract

The peripheral nervous system has the remarkable capacity for spontaneous regeneration after injury. Despite this inherent capability, clinical outcomes remain poor and are often hallmarked by pathophysiologic neuroma formation and limited neurologic recovery. Inflammation is fundamental for successful regeneration but can propagate pathophysiologic outcomes when aberrantly activated. Although the numerous mechanisms whereby nerve regeneration is derailed into a pathophysiologic state have yet to be established, a growing body of research has elaborated the interplay of neuroimmune interactions in successful nerve regeneration. In this review, we synthesize the current understanding of neuroimmune interactions in traumatic peripheral nerve injury, regeneration, and pathophysiology across three domains: (1) resident immune response; (2) innate immune response; and (3) adaptive immune response. Here, we examine the temporal dynamics of immune cell recruitment, polarization, and functional contributions during Wallerian degeneration and regeneration. We propose potential mechanisms of pathophysiologic regeneration, including failed inflammatory resolution and neuroimmune interactions that sustain maladaptive responses. Finally, we aim to connect these basic science mechanisms to current therapeutic strategies. Specifically, we detail how pharmacologic interventions, cellular therapies, energetic stimulation, and hydrogel or conduir-based approaches may modulate the immune response and shape the microenvironment to improve regenerative outcomes. Collectively, a comprehensive understanding of the bidirectional interactions among neural, immune, and other local cell types within the injury microenvironment is critical for developing strategies to improve nerve regeneration and neurologic outcomes.

## Full-text entities

- **Genes:** SPINK5 (serine peptidase inhibitor Kazal type 5) [NCBI Gene 11005] {aka LEKTI, LETKI, NETS, NS, VAKTI}, Myd88 (myeloid differentiation primary response gene 88) [NCBI Gene 17874], ERVK-3 (endogenous retrovirus group K member 3) [NCBI Gene 100862689] {aka c3_B}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, AIF1 (allograft inflammatory factor 1) [NCBI Gene 199] {aka AIF-1, IBA1, IRT-1, IRT1}, Ly6c1 (lymphocyte antigen 6 family member C1) [NCBI Gene 17067] {aka Ly-6C, Ly-6C1, Ly6c}, Ccl12 (C-C motif chemokine ligand 12) [NCBI Gene 20293] {aka MCP-5, Scya12}, Il1 (interleukin 1 complex) [NCBI Gene 111343] {aka Il-1}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, LLGL1 (LLGL scribble cell polarity complex component 1) [NCBI Gene 3996] {aka DLG4, HUGL, HUGL-1, HUGL1, LLGL, Lgl1}, GDNF (glial cell derived neurotrophic factor) [NCBI Gene 2668] {aka ATF, ATF1, ATF2, HFB1-GDNF, HSCR3}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, CNTNAP2 (contactin associated protein 2) [NCBI Gene 26047] {aka AUTS15, CASPR2, CDFE, NRXN4, PTHSL1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, ITGAM (integrin subunit alpha M) [NCBI Gene 3684] {aka CD11B, CR3A, HNA-4, MAC-1, MAC1A, MO1A}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, Cd68 (CD68 antigen) [NCBI Gene 12514] {aka Lamp4, Scard1, gp110}, Tlr2 (toll-like receptor 2) [NCBI Gene 24088] {aka Ly105}, CRYGC (crystallin gamma C) [NCBI Gene 1420] {aka CCL, CRYG3, CTRCT2}, Arg1 (arginase, liver) [NCBI Gene 11846] {aka AI, Arg-1, PGIF}, Ccl3 (C-C motif chemokine ligand 3) [NCBI Gene 20302] {aka G0S19-1, LD78alpha, MIP-1alpha, MIP1-(a), MIP1-alpha, Mip1a}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, C4B (complement C4B (Chido/Rodgers blood group)) [NCBI Gene 721] {aka C4B1, C4B12, C4B3, C4B5, C4BD, C4F}, CLDN1 (claudin 1) [NCBI Gene 9076] {aka CLD1, ILVASC, SEMP1}, Ccl7 (C-C motif chemokine ligand 7) [NCBI Gene 20306] {aka MCP-3, Scya7, fic, marc, mcp3}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, NGF (nerve growth factor) [NCBI Gene 4803] {aka Beta-NGF, HSAN5, NGFB}, Ccr2 (C-C motif chemokine receptor 2) [NCBI Gene 12772] {aka Cc-ckr-2, Ccr2a, Ccr2b, Ckr2, Ckr2a, Ckr2b}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442] {aka VR1}, VIM (vimentin) [NCBI Gene 7431], MMP13 (matrix metallopeptidase 13) [NCBI Gene 4322] {aka CLG3, MANDP1, MDST, MMP-13}, Smo (smoothened, frizzled class receptor) [NCBI Gene 319757] {aka E130215L21Rik, Smoh, bnb, smoothened}, Icam1 (intercellular adhesion molecule 1) [NCBI Gene 15894] {aka CD54, Icam-1, Ly-47, MALA-2}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Ccl6 (C-C motif chemokine ligand 6) [NCBI Gene 20305] {aka MRP-1, Scya6, c10}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, IL23A (interleukin 23 subunit alpha) [NCBI Gene 51561] {aka IL-23, IL-23A, IL23P19, P19, SGRF}, Mertk (MER proto-oncogene tyrosine kinase) [NCBI Gene 17289] {aka Eyk, Mer, Nyk, nmf12}, C5 (complement C5) [NCBI Gene 727] {aka C5D, C5a, C5b, CPAMD4, ECLZB}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Ccl8 (C-C motif chemokine ligand 8) [NCBI Gene 20307] {aka 1810063B20Rik, HC14, MCP-2, Mcp2, Scya8}, Ccr5 (C-C motif chemokine receptor 5) [NCBI Gene 12774] {aka AM4-7, CD195, Cmkbr5}, S100A1 (S100 calcium binding protein A1) [NCBI Gene 6271] {aka S100, S100-alpha, S100A}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, OCLN (occludin) [NCBI Gene 100506658] {aka BLCPMG, PPP1R115, PTORCH1}
- **Diseases:** necrotic (MESH:D009336), WD (MESH:D014855), allodynia (MESH:D006930), spinal cord injury (MESH:D013119), seizures (MESH:D012640), crush (MESH:D003444), C3 (MESH:C565169), neurologic deficits (MESH:D009461), ischemia (MESH:D007511), hypoxia (MESH:D000860), neurologic disability (MESH:D009069), motor and sensory dysfunction (MESH:C536988), neuroma (MESH:D009463), MR (MESH:D008944), limbic encephalitis (MESH:D020363), depression (MESH:D003866), chronic pain (MESH:D059350), hypoxic (MESH:D002534), Morvan syndrome (OMIM:201300), autoimmune (MESH:D001327), neuropathic pain (MESH:D009437), sciatic nerve injury (MESH:D020426), inflammatory drugs (MESH:D000081015), inflammatory cytokines (MESH:D000080424), NET (MESH:C536657), axonal degeneration (MESH:D009410), gut dysmotility (MESH:D015154), stroke (MESH:D020521), peripheral nerve trauma (MESH:D010523), cancer (MESH:D009369), psychosis (MESH:D011618), sensory deficits (MESH:D012678), neurotoxicity (MESH:D020258), infection (MESH:D007239), psychiatric (MESH:D001523), anxiety (MESH:D001007), nerve transection injury (MESH:D061220), Neuroinflammation (MESH:D000090862), edema (MESH:D004487), CNS injury (MESH:D002493), laceration (MESH:D022125), traumatic brain injury (MESH:D000070642), rheumatoid arthritis (MESH:D001172), fibrosis (MESH:D005355), Inflammation (MESH:D007249), injuries (MESH:D014947), neurodegeneration (MESH:D019636), compression (MESH:D009408), gap (MESH:C562538), nerve injuries (MESH:D000080902), crush injury (MESH:D000071576), Peripheral nerve injuries (MESH:D059348), pain (MESH:D010146), neurologic injury (MESH:D020196)
- **Chemicals:** polyurethane (MESH:D011140), polydopamine (MESH:C568283), aniline (MESH:C023650), magnesium (MESH:D008274), water (MESH:D014867), ACh (MESH:D000109), minocycline (MESH:D008911), lipopolysaccharide (MESH:D008070), ganciclovir (MESH:D015774), silicon (MESH:D012825), Anti- (-), chitosan (MESH:D048271), FK506 (MESH:D016559), silica (MESH:D012822)
- **Species:** Bombyx mori (domestic silkworm, species) [taxon 7091], Mus musculus (house mouse, species) [taxon 10090], Staphylococcus aureus (species) [taxon 1280], Homo sapiens (human, species) [taxon 9606], Danio rerio (leopard danio, species) [taxon 7955]
- **Cell lines:** fibroblasts — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950766/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950766/full.md

## References

178 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950766/full.md

---
Source: https://tomesphere.com/paper/PMC12950766